Mecobalamin ( DrugBank: Mecobalamin )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症2
70広範脊柱管狭窄症1

2. 筋萎縮性側索硬化症


臨床試験数 : 624 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00445172
(ClinicalTrials.gov)
February 20086/3/2007A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)Drug: E0302 (mecobalamin)Eisai Co., Ltd.NULLCompleted20 YearsN/AAll135Phase 2/Phase 3Japan
2NCT00444613
(ClinicalTrials.gov)
April 20076/3/2007A Study in Patients With Amyotrophic Lateral Sclerosis (ALS)A Phase II/III Study in Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)Drug: E0302 (mecobalamin);Drug: PlaceboEisai Co., Ltd.NULLCompleted20 YearsN/ABoth373Phase 2/Phase 3Japan

70. 広範脊柱管狭窄症


臨床試験数 : 96 薬物数 : 203 - (DrugBank : 60) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 89
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2100046515
2021-06-012021-05-18To Evaluate the Clinical Efficacy of Zhuanyao Decoction in the Treatment of Degenerative Lumbar Spinal Stenosis Based on the Theory of 'Yanghua Qi'To Evaluate the Clinical Efficacy of Zhuanyao Decoction in the Treatment of Degenerative Lumbar Spinal Stenosis Based on the Theory of 'Yanghua Qi' Degenerative lumbar spinal stenosisTreatment group:Zhuanyaotang Decoction granules + Mecobalamin tablets simulation agent+ Celecoxib capsules simulation agent;Control group:Methobalamin tablet + Celecoxib capsule + Zhuanyaotang Decoction granule simulation agent;Wang Jing Hospital, Chinese Academy of Traditional Chinese MedicineNULLRecruiting4570BothTreatment group:52;Control group:52;N/AChina